Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT07122063
What this trial is testing

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd. 266
Not applicableStudy completedNCT03123263
What this trial is testing

Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer

Who this might be right for
Breast Cancer
Texas Tech University Health Sciences Center, El Paso 60
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Not applicableLooking for participantsNCT06916637
What this trial is testing

Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, HER2-Expression
The Affiliated Hospital of Qingdao University 40
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Early research (Phase 1)Study completedNCT02952729
What this trial is testing

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

Who this might be right for
Advanced Breast CancerAdvanced Nonsmall Cell Lung CancerAdvanced Gastric Cancer
Mersana Therapeutics 120
Early research (Phase 1)Study completedNCT00889954
What this trial is testing

Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy

Who this might be right for
HER2 Positive Malignancies
Baylor College of Medicine 20
Testing effectiveness (Phase 2)Looking for participantsNCT06695845
What this trial is testing

Zanidatamab in Patients With HER2-expressing Tumors

Who this might be right for
Breast CancerGastric CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals 200
Early research (Phase 1)Study completedNCT04513223
What this trial is testing

SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Gastric CancerColorectal Cancer
Jiangsu HengRui Medicine Co., Ltd. 101
Testing effectiveness (Phase 2)Ended earlyNCT05311176
What this trial is testing

IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

Who this might be right for
Gastric CancerCancer of StomachGastric Adenocarcinoma+3 more
Imugene Limited 7
Not applicableUnknownNCT06492447
What this trial is testing

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

Who this might be right for
HER 2 Low-expressing Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Early research (Phase 1)Study completedNCT00005023
What this trial is testing

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Who this might be right for
Breast CancerLung CancerOvarian Cancer
University of Washington
Early research (Phase 1)Active Not RecruitingNCT04294628
What this trial is testing

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 62
Large-scale testing (Phase 3)Active Not RecruitingNCT06561607
What this trial is testing

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Testing effectiveness (Phase 2)Looking for participantsNCT07646145
What this trial is testing

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT01779050
What this trial is testing

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT04379596
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Who this might be right for
Gastric Cancer
AstraZeneca 452
Next Page